Newsroom
Category
April 1, 2022
Structural racism, rather than disease, leads to inequities, authors write Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients in a study published March 28 in JAMA Network Open. Investigators of the COVID-19 and Cancer Consortium (https://ccc19.org/), which includes more than 125 cancer centers and other organizations, studied […]
April 1, 2022
Kevin Koronowski, PhD, assistant professor in the Department of Biochemistry and Structural Biology in the Joe R. and Teresa Lozano Long School of Medicine and the Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, received a UT System Rising STARs (Science and Technology Acquisition and Retention) award in […]
April 1, 2022
Daohong Zhou, MD, a professor with tenure in the Department of Biochemistry and Structural Biology in the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio, has received a UT System Faculty STARs award in the amount of $1,487,563 to support his drug discovery research.
March 18, 2022
Ruben A. Mesa, MD, FACP, professor of medicine and executive director of the Mays Cancer Center at UT Health San Antonio, testified on clinical trial diversity yesterday (March 17, 2022) before the House Committee on Energy and Commerce. The hearing was titled “The Future of Medicine: Legislation to Encourage Innovation and Improve Oversight.” Dr. Mesa […]
March 17, 2022
Cancer and virology researcher Reuben Harris, PhD, has been named chairman of the Department of Biochemistry and Structural Biology at UT Health San Antonio. The department is in the Joe R. and Teresa Lozano Long School of Medicine. Dr. Harris, a professor with tenure, will assume his duties effective April 11, 2022, announced Robert Hromas, […]
March 10, 2022
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division chief of hematology and medical oncology at UT […]
